Core Insights - InspireMD, Inc. has appointed Michael Lawless as Chief Financial Officer, effective on or prior to June 30, 2025, succeeding Craig Shore who has held the position for nearly 15 years [1][3] Company Overview - InspireMD is focused on developing the CGuard™ Prime carotid stent system aimed at treating carotid artery disease and preventing strokes [1][7] - The company aims to establish its proprietary MicroNet technology as the industry standard for carotid stenting, emphasizing outstanding acute results and durable, stroke-free long-term outcomes [7] Leadership Transition - Michael Lawless brings extensive experience as a public company CFO, having served as CFO of Lifeward and previously the $200 million Life Sciences unit of Brooks Automation [2] - The CEO of InspireMD expressed enthusiasm for Lawless's expertise to lead the company’s growth, particularly with the upcoming launch of CGuard Prime in the U.S. market [3] Inducement Grant Details - As part of his appointment, Lawless will receive 465,000 shares of restricted stock and stock options to purchase 212,000 shares of common stock, approved by the Compensation Committee [4] - The stock options will vest over three years, with one-third vesting on the first anniversary and the remainder in two equal installments on the second and third anniversaries, contingent on continuous employment [5]

Core Viewpoint - InspireMD, Inc. is set to present at the Bank of America 2025 Healthcare Conference, highlighting its focus on carotid artery disease treatment and stroke prevention through its CGuard™ Prime carotid stent system [1]. Company Overview - InspireMD, Inc. develops the CGuard™ Prime carotid stent system aimed at treating carotid artery disease and preventing strokes [1]. - The company utilizes its proprietary MicroNet® technology to establish its products as the industry standard for carotid stenting, emphasizing superior acute results and long-term stroke-free outcomes [2]. Event Details - The presentation at the Bank of America 2025 Healthcare Conference is scheduled for May 14, 2025, at 1:15 PM Eastern Time / 10:15 AM Pacific Time [1]. - A live audio webcast and replay of the presentation will be available for 90 days on the company's website [2].

Core Viewpoint - InspireMD, Inc. is set to release its first quarter 2025 financial results on May 9, 2025, and will host a conference call to discuss these results and recent highlights [1]. Company Overview - InspireMD, Inc. develops the CGuard™ Prime carotid stent system aimed at treating carotid artery disease (CAD) and preventing strokes [1]. - The company utilizes proprietary MicroNet technology to establish its products as the industry standard for carotid stenting, focusing on delivering excellent acute results and long-term, stroke-free outcomes [3]. - InspireMD's common stock is traded on Nasdaq under the ticker symbol NSPR [3]. Conference Call Details - The conference call will take place at 8:30 a.m. Eastern Time on May 9, 2025, and will be accessible via telephone and webcast [1][2]. - Domestic callers can dial 1-800-579-2543, while international callers can reach the call at 1-785-424-1789 [2]. - A replay of the webinar will be available shortly after the call and archived on InspireMD's website [2].

Core Viewpoint - InspireMD, Inc. is set to present at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, showcasing its CGuard™ Prime carotid stent system aimed at treating carotid artery disease and preventing strokes [1]. Company Overview - InspireMD, Inc. develops the CGuard™ Prime carotid stent system, utilizing proprietary MicroNet® technology to establish its products as the industry standard for carotid stenting, focusing on achieving excellent acute results and long-term stroke-free outcomes [2]. - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates investors through its website [2]. Event Details - The presentation will be accessible via a live audio webcast, with a replay available for 90 days on the company's website [2].

Core Insights - InspireMD, Inc. has made significant progress in 2024, particularly with the CGuard Prime carotid stent system, which is on track for potential U.S. approval in the first half of 2025 [3][10] - The company reported a revenue increase of 10.7% in Q4 2024 compared to Q4 2023, driven by growth in both new and existing markets [4][11] - Despite revenue growth, gross profit decreased due to rising costs, leading to a net loss of $9.17 million in Q4 2024, compared to a net loss of $5.41 million in Q4 2023 [5][7][16] Recent Business Highlights - The CEO highlighted the advancement of CGuard Prime towards FDA approval and the initiation of the CGUARDIANS II pivotal study for the TCAR market [3][10] - The company established its headquarters in Miami, Florida, to support the anticipated U.S. commercial launch of CGuard Prime [10] Financial Results for Q4 2024 - Total revenue for Q4 2024 was $1.95 million, up from $1.76 million in Q4 2023 [4][23] - Gross profit for Q4 2024 was $469,000, down from $505,000 in Q4 2023, reflecting increased costs of goods sold [5][23] - Operating expenses rose to $9.84 million in Q4 2024, a 55.8% increase from $6.31 million in Q4 2023, primarily due to higher salaries and clinical expenses [6][23] Financial Results for Full Year 2024 - For the full year 2024, revenue increased by 13.0% to $7.01 million from $6.21 million in 2023 [11][23] - Gross profit for the full year decreased by 16.7% to $1.51 million, with a gross margin decline to 21.5% from 29.1% in 2023 [12][13][23] - The net loss for the full year totaled $32.01 million, compared to a net loss of $19.92 million in 2023 [16][23] Cash Position - As of December 31, 2024, cash and cash equivalents and marketable securities totaled $34.64 million, down from $39.02 million a year earlier [8][23]